Icagen, a biopharmaceutical firm developing drugs that treat by modulating ion channels, revised its estimated offering price to $8, from an original range of $10 to $12. The company still plans to offer 5 million shares, which would result in a revised estimated market cap of $172 million. JP Morgan and UBS Investment Bank are joint book runners on the deal. The deal is expected to price this week.
